Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Qingdao Gaoce Technology
688556
5
Aerospace Nanhu Electronic Information Technology
688552
US OptionsDetailed Quotes
ALNY250516P155000
- 0.75
- 0.000.00%
15min DelayTrading Mar 24 11:53 ET
0.00High0.00Low
0.00Open0.75Pre Close0 Volume2 Open Interest155.00Strike Price0.00Turnover190.63%IV40.40%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.0243Delta0.0008Gamma345.05Leverage Ratio-0.2397Theta-0.0015Rho-8.37Eff Leverage0.0222Vega
Alnylam Pharmaceuticals Newsroom
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $280
Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $500
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
Research Alert: CFRA Retains Buy Opinion On Shares Of Alnylam Pharmaceuticals, Inc.
Analyst Estimates: Here's What Brokers Think Of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) After Its First-Quarter Report
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $287 to $371
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $325
Alnylam Pharmaceuticals Analyst Ratings
Alnylam Pharmaceuticals Reports Strong Start to 2025
Earnings Call Summary | Alnylam Pharmaceuticals(ALNY.US) Q1 2025 Earnings Conference
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Research Alert: Alny Q1 Results Point To A Strong Start To The Year; Guidance Maintained
Alnylam Q1 Non-GAAP Net Loss Narrows, Revenue Rises
Alnylam Pharmaceuticals | 10-Q: Q1 2025 Earnings Report
Alnylam Sees FY25 Non-GAAP Operating Income Achieving Profitability >ALNY
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
